Here are the S-3 shelf registrations from Harvard Bioscience Inc (HBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow HBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HBIO filings page.
Harvard Bioscience, Inc. has filed a resale registration covering up to 9,500,000 shares of its common stock for sale from time to time by selling securityholders. These shares consist of up to 2,000,000 shares issuable upon exercise of warrants at $0.50 per share and up to 7,500,000 shares issuable upon conversion of a $7.5 million Term C convertible loan at $1.00 per share.
The company is not selling shares in this offering and will receive no proceeds from resales, other than up to $1.0 million if the warrants are exercised for cash, which would be used for working capital and general corporate purposes. There were 44,719,894 shares of common stock outstanding as of December 31, 2025, and the stock trades on Nasdaq under the symbol HBIO. The filing notes that investing in these securities involves a high degree of risk and highlights Harvard Bioscience’s status as a smaller reporting company with scaled disclosure requirements.